Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,910,289
  • Shares Outstanding, K 40,090
  • Annual Sales, $ 276,370 K
  • Annual Income, $ -37,950 K
  • 36-Month Beta 2.17
  • Price/Sales 7.13
  • Price/Cash Flow 161.09
  • Price/Book 7.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.35 +5.70%
on 07/25/17
51.10 -16.54%
on 07/13/17
-4.80 (-10.12%)
since 06/23/17
3-Month
40.35 +5.70%
on 07/25/17
52.47 -18.72%
on 05/11/17
-3.65 (-7.88%)
since 04/25/17
52-Week
29.95 +42.40%
on 12/02/16
58.95 -27.65%
on 03/01/17
+4.99 (+13.25%)
since 07/25/16

Most Recent Stories

More News
Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will...

PCRX : 42.65 (-12.42%)
Pacira Pharmaceu Set to Possibly Rebound After Yesterday's Selloff of 12.99%

Pacira Pharmaceu (NYSE:PCRX) traded in a range yesterday that spanned from a low of $40.35 to a high of $45.00. Yesterday, the shares fell 13.0%, which took the trading range below the 3-day low of $47.50...

PCRX : 42.65 (-12.42%)
Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association...

PCRX : 42.65 (-12.42%)
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the JMP Securities Life Sciences Conference at 3:00 PM ET on Tuesday, June 20,...

PCRX : 42.65 (-12.42%)
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX : 42.65 (-12.42%)
Pacira Pharmaceuticals Announces Resignation of James Scibetta

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James Scibetta is resigning as the company's president to become chief executive officer of an undisclosed private early-stage oncology company....

PCRX : 42.65 (-12.42%)
Investor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 8:30 AM Eastern Time....

PCRX : 42.65 (-12.42%)
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option

According to a new national survey of over 1,500 oral surgery patients or their parents, more than seven in 10 respondents indicated they would opt for a non-opioid medication to treat postsurgical pain...

PCRX : 42.65 (-12.42%)
How These Generic Drugs Stocks are Faring? -- Medicines Co., Ironwood Pharma, Pacira Pharma, and Supernus Pharma

Stock-Callers.com has issued research reports on: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals...

IRWD : 17.04 (-0.41%)
MDCO : 38.73 (-1.25%)
SUPN : 42.80 (-1.61%)
PCRX : 42.65 (-12.42%)
Pacira Focuses on Lead Candidate Exparel's Label Expansion

We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

HSKA : 103.31 (+0.21%)
GALE : 0.56 (-4.24%)
PCRX : 42.65 (-12.42%)
RTRX : 20.35 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Support & Resistance

2nd Resistance Point 47.32
1st Resistance Point 44.98
Last Price 42.65
1st Support Level 40.33
2nd Support Level 38.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.